List view / Grid view
In fast paced environment where routine testing needs to be efficient, fast, accurate and secure, documentation and data transfer is increasingly important.
Watch our quick learning and learn in only 10 minutes what key challenges manufacturers are facing when selecting media for media fill tests and how to overcome them.
The EMA has built up an infrastructure to allow for the monitoring of COVID-19 treatments and vaccines used in clinical practice.
A batch of Nitrofurantoin and all unexpired stock of Desmopressin nasal spray are being recalled in the UK, the MHRA has announced.
Facing challenges with your small or large molecules analysis & QC? Interested to learn from your industry peers? Ask us any question.
The alliance between Chronicled and Deloitte intends to enhance security and efficiency in the pharma supply chain by bring to market new blockchain-powered solutions.
Quality control testing instrumentation solutions for GMP manufacturing. From raw materials QC through production QC and final product QC.
This whitepaper from Beckman Coulter discusses GMP Cleanrooms Classification and Routine Environmental Monitoring.
This whitepaper from Beckman Coulter explores GMP cleanroom routine environmental monitoring and data integrity.
According to research, the rise in demand for high-quality cannabis will also drive growth in the cannabis testing market, where new technologies are needed to overcome current limitations.
Integrated electronic SOPs and maps are “all in the box” to help reduce errors.
Maintaining Data Integrity. Did you know that lack of data integrity has been a top reason for FDA Drug GMP warning letters?
The new MET ONE 3400+ Series PortableAirborne Particle Counter automates environmental monitoring for GMP cleanroom compliance.
Over a year since the EU FMD came into force, false alerts remain a problem preventing the realisation of the full benefits of the directive. Grant Courtney examines the reasons behind these alerts occurring and looks at the action stakeholders must now take.
The agency’s opinion will require companies to take measures to reduce nitrosamine impurities in medicines and carry out and action the results of risk assessments.
